

Clinical instrumental assessment of the efficacy of a treatment for hair care (food supplement & cosmetic product) claimed to decrease hair loss

ADN COMUNITY SL

- ☐ **REDENHAIR HAIR REGENERATOR SERUM Forte -
Tónico capilar con acción anti-caída**
- ☐ **REDENHAIR Hair Nutrition Supplement**

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it

COMPLIFE
GROUP

KEY PERSONNEL

Customer

ADN COMUNITY SL
C/MALLORCA 61-63
08029, Barcelona, Spain

Investigator

Dr Enza CESTONE
Degree in Medicine and Surgery, Specialist in Dermatology and Venereology
Consultant to Farcoderm s.r.l.

Study director & Quality control

Dr Vincenzo Nobile
International Development Coordinator
Biologist

Farcoderm srl

Farcoderm Srl
Via Angelini, 21
27028 San Martino Siccomario (PV)
tel. +39-0382 25504 fax. +39-0382 536006
information@farcoderm.com

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it



TABLE OF CONTENTS

STUDY DESIGN	4
1.1. Title	4
1.2. Aim of the study.....	4
1.3. Tested products	4
1.3.1. Information provided by the Customer	4
1.4. Ethical requirements.....	5
1.5. Subjects participating in the study.....	5
1.5.1. Subjects enrolment	5
1.5.1.1. Inclusion criteria	5
1.5.1.2. Non-inclusion criteria	5
1.6. Study development.....	6
1.7. MATERIALS AND METHODS	7
1.7.1. Phototrichogram	7
1.7.2. Overall hair volume and overall hair appearance	7
1.7.3. Digital pictures	7
1.7.4. Self-assessment questionnaire	7
1.8. Results and statistic	7
1.8.1. Results.....	7
1.8.2. Statistical analysis	8
RESULTS: PHOTOTRICHOGRAM	9
RESULTS: CLINICAL ASSESSMENT - OVERALL HAIR VOLUME AND APPERANCE.....	10
RESULTS: SELF-ASSESSMENT AFTER 30 DAYS	11
RESULTS: SELF-ASSESSMENT AFTER 60 DAYS	12
RESULTS: SELF-ASSESSMENT AFTER 90 DAYS	13
RESULTS: SELF-ASSESSMENT SUMMARY	14
CONCLUSIONS.....	15

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it



STUDY DESIGN

1.1. Title

Clinical instrumental assessment of the efficacy of a treatment for hair care (food supplement & cosmetic product) claimed to decrease hair loss.

1.2. Aim of the study

The study is aimed to assess the efficacy of a treatment for haircare (food supplement & cosmetic product) claimed to decrease hair loss. In order to reach this goal a clinical-instrumental study is carried out on 30 healthy male subjects showing alopecia type from I to III vertex. Product efficacy is assessed by means of phototrichogram and clinical assessment. Phototrichogram and clinical assessments are integrated by the self-assessment carried out by the subjects participating in the study.

1.3. Tested products

1.3.1. Information provided by the Customer

☒ Product identification

REDENHAIR HAIR REGENERATOR SERUM Forte - Tónico capilar con acción anti-caída
REDENHAIR Hair Nutrition Supplement

☒ Way of use

- Serum. Shake before use. Apply 2 pipette per day on the scalp and slightly massage. Do not wash after product use. Avoid the contact with eyes and mucosa. Keep the product out of the reach of children.
- Food supplement. Two (2) capsules per day with a glass of water ($\approx$ 125 ml) with meals. Do not exceed recommended doses. This product should not be used as a substitute neither for a varied and balanced diet nor for a healthy way of life. Keep the product out of the reach of children. Store in a cool dry place (15-25°C) avoiding light exposure.

☒ The tested cosmetic product conforms to Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance) and to its annexes.

☒ Products to be tested are safe under normal or reasonably foreseeable conditions of use.

☒ The food supplement is notified to the Spanish Health Ministry.

☒ Receipt (ref. no NUT_PL_AS 3000/1) of notification to the French "Direction générale Animaux, Végétaux et Alimentation".

☒ Products composition

- Quantitative INCI formula (cosmetic product). AQUA, ROSMARINUS OFFICINALIS LEAF WATER, ETHOXYDIGLYCOL, BUTYLENE GLYCOL, GLYCERIN, PROPANEDIOL, HYDROXYPROPYL METHYLCELLULOSE, SODIUM LAUROYL LACTYLATE, SODIUM BENZOATE, ISOMALT, ARGININE, LACTIC ACID, POTASSIUM SORBATE, CITRIC ACID, DEXTRAN, GLYCINE SOJA GERM EXTRACT, TRITICUM VULGARE GERM EXTRACT, SODIUM PCA, PPG-26-BUTETH-26, SODIUM LACTATE, HYDROLYZED CERATONIA SILIQUA SEED EXTRACT, PEG-40 HYDROGENATED CASTOR OIL, GLYCINE, ZEA MAYS STARCH, LARIX EUROPAEA WOOD EXTRACT, SODIUM METABISULFITE, ASPARTIC ACID, GLUCONOLACTONE, PCA, ACETYL TETRAPEPTIDE-3, PIPER NIGRUM FRUIT EXTRACT, TRIFOLIUM PRATENSE FLOWER EXTRACT, SCUTELLARIA BAICALENSIS ROOT EXTRACT, SERENOA SERRULATA FRUIT EXTRACT, ALANINE, HYDROLYZED CORN PROTEIN, SERINE, ARGANIA SPINOSA CALLUS CULTURE EXTRACT, LECITHIN, VALINE, CAMELLIA SINENSIS LEAF EXTRACT, ZINC CHLORIDE, ISOLEUCINE, PHENOXYETHANOL, PROLINE, THREONINE, APIGENIN, INGA ALBA BARK EXTRACT, HYDROLYZED ADANSONIA DIGITATA EXTRACT, OLEANOLIC ACID, HISTIDINE, PHENYLALANINE, BIOTINOYL TRIPEPTIDE-1, GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE, POLYQUATERNIUM-7, CALCIUM GLUCONATE.
- Ingredients (food supplement). EXTRACTO SECO DE SABAL, L-CISTEÍNA ANHIDRA, CÁPSULA (GELATINA, COLORANTES E172, E171, E122), EXTRACTO SECO DE TÉ VERDE, EXTRACTOS SECO DE POLÍGONO, METILSULFONILMETANO (MSM), CELULOSA MICROCRISTALINA (AGENTE DE CARGA), EXTRACTO SECO DE CÚRCUMA, ZINC (COMO ZINC CARBONATO), EXTRACTO SECO DEL COLA DE CABALLO, HIERRO (COME HIERRO PIRÓFOSFATO), ANTIAGLOMERANTE (DÍOXIDO SILICE), CALCIO (COMO CALCIO CARBONATO), COBRE (COME COBRE GLUCONATO), ANTIAGLOMERANTE (ESTEARATO MAGNESIO), VITAMINA B5 (PANTOTENATO DE CALCIO), VITAMINA B6 (PIRIDOXINA), EXTRACTO SECO DE PIMENTERO NEGRO, VITAMINA B8 (BIOTINA).
- Base shampoo/conditioner (Esselunga Neutro & Delicato Shampoo & Balsamo 2 in 1 con pantenolo e olio di Jojoba)*. AQUA, SODIUM LAURETH SULFATE, COCAMIDOPROPYL BETAINE, POLISORBATE 20, COCO GLUCOSIDE, GLYCERYL OLEATE, ACRYLATES COPOLYMER, PARFUM, PEG-4 DISTEARYL ETHER, PEG-7 GLYCERYL COCOATE, C12-13 ALKYL LACTATE, AMODIMETHICONE, CITRIC ACID, PROPYLENE GLYCOL, PANTHENOL, DISTEARYL ETHER, JOJOBA OIL, PEG-8 ESTERS, TRIDECETH-12, DICAPRYLYL ETHER, CETRIMONIUM CHLORIDE, SODIUM BENZOATE, POTASSIUM SORBATE, SODIUM HYDROXIDE, TETRASODIUM EDTA, SODIUM CHLORIDE, METHYLISOTHIAZOLINONE, CITRONELLOL, LINALOOL.

* during the study period subjects use a neutral shampoo/conditioner in order to standardize hair washing.

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it



1.4. Ethical requirements

The study is carried out according the ethical requirements listed here below.

- 1.4.1. All participants in the study are healthy volunteers, aged over 18 years old.
- 1.4.2. All participants in the study are screened and enrolled under the supervision of an experimenter, according to specific inclusion/non-inclusion criteria.
- 1.4.3. Volunteers participation in the study is free.
- 1.4.4. All participants in the study are informed of the aim and the nature of the study.
- 1.4.5. All participants in the study are informed of the possible risks involved in the study.
- 1.4.6. All participants in the study sign a written consent form before the study begins.
- 1.4.7. Before volunteers are exposed to the tested product, all safety information regarding the product and its individual ingredients are assessed.
- 1.4.7. All the study procedures are carried out in compliance with the ethical principles for medical research (Ethical Principles for Medical Research Involving Human Subjects, Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and its amendment)
- 1.4.9 All the precautions are taken in order to avoid adverse reactions occurrence.
- 1.4.10 In case of non-expected/adverse reaction occurrence the medical investigating specialist evaluate the severity of the reaction (reporting it in the data collecting sheet of the volunteer) and as a consequence start the appropriate therapy.

1.5. Subjects participating in the study

1.5.1. Subjects enrolment

The subjects participating in the study are screened and enrolled in the study under the supervision of a board certified dermatologist from a panel of healthy male subjects, in accordance with the inclusion and non-inclusion criteria reported here below.

1.5.1.1. Inclusion criteria

- ☒ Good general health
- ☒ Male suffering from Androgenic Alopecia (AGA, score from I to III vertex according to Hamilton-Norwood scale, see figure 1)
- ☒ Caucasian ethnicity
- ☒ Age older than 18 years old
- ☒ Adequate rest period between two similar study
- ☒ Willingness to not use products for hair care (both topic and systemic) likely to interfere with the products to be tested
- ☒ Willingness to not use, during all the study period, products for hair care other than the products supplied
- ☒ Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, haircut, etc.)

1.5.1.2. Non-inclusion criteria

- ☒ Subject do not meet the inclusion criteria
- ☒ Alimentary/Eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)
- ☒ Food allergy or food intolerances
- ☒ Past history of allergy to cosmetics, toiletries, sunscreens and/or topical medications
- ☒ Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications
- ☒ Pharmacological treatment (topic or systemic) know to interfere with the tested product or having effects on metabolism
- ☒ Severe concurrent diseases
- ☒ Any condition that the principal investigator deems inappropriate for participation

Page 5 out of 17

Farcoderm srl


Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legatmail.it



- ✗ Drug addict, alcoholic
- ✗ Subject protected by the law (under guardianship or hospitalized in a public or private institution for a reason other than the research) or incarcerated
- ✗ Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development or impaired cerebral function

Figure 1 Hamilton-Norwood scale.




The Hamilton-Norwood¹ scale is widely used by professionals to classify the degree of baldness of patients. The typical pattern of hair loss is divided into seven categories. No hair loss is termed 'type I'. Minor recession of the frontal hairline is termed 'type II'. Type III indicates further frontal loss, and is considered 'cosmetically significant'. The subset of type III, termed 'III vertex', shows significant frontal recession coupled with hair loss from the vertex region of the scalp. Types IV-VI show further frontal and vertex loss, culminating in type VII, in which only the occipital scalp region maintains significant amounts of hair.

¹ Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359-65.

1.6. Study development

The study flow and the schedule of assessments chart is reported in figure 2.

Figure 2 Study flow and schedule of assessments chart.



Legend

PT Phototrichogram, DA Dermatological assessment, PH Digital pictures, SA Self-assessment questionnaire

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it

1.7. MATERIALS AND METHODS

In the sections here below are reported the materials and the methods employed in the study.

1.7.1. Phototrichogram

A transitional area of hair loss between normal hair and the balding area of 1.8 cm² is defined using a stencil template and chosen for clipping. The clipped hair within the target area are dyed for gray or fair hairs with a commercially available solution (RefectoCil®, GW Cosmetics GmbH, Leopoldsdorf, Germany) in order to enhance their contrast. Thereafter, the dyed hairs are cleansed using an alcoholic solution and digital images are taken while the area is still wet with a digital close-up camera. Images are taken at day 0, immediately after clipping, and 2 days after clipping. These two photographs are then examined by a software system that is able to recognize individual hair fibers in the photographs. By comparing the two photographs, the computer can determine which hairs are growing (anagen hairs) and which are not (telogen hairs). In addition, hair density is assessed as the total number of hairs per cm².

1.7.2. Overall hair volume and overall hair appearance

The dermatologist evaluates the overall hair volume and the overall hair appearance according the clinical score scales reported in table 1.7.2.1. The overall hair volume changes during the clinical study are assessed by the dermatologist on digital pictures.

Table 1.7.2.1 Overall hair volume variation scoring.

	Hair volume		Hair appearance
Greatly decreased	-3	Greatly worsened	-3
Moderately decreased	-2	Moderately worsened	-2
Slightly decreased	-1	Slightly worsened	-1
No change	0	No change	0
Slightly increased	1	Slightly improved	1
Moderately increased	2	Moderately improved	2
Greatly increased	3	Greatly improved	3

1.7.3. Digital pictures

Digital pictures are taken, under standard lighting conditions, using a professional digital reflex camera NIKON D300 digital camera, Nikon Corporation Tokyo, Japan) equipped with a macro-objective (AF-S Micro NIKKOR 60mm f/2.8G ED, Nikon Corporation Tokyo, Japan), an independent flash system (Kit R1C1, Nikon Corporation Tokyo, Japan) and with cross- and parallel-polarized filters. Four images are taken for each subject participating in the study, as follows: a) 1 cross- and 1 parallel-polarized picture is taken at the vertex level, and b) 1 cross- and 1 parallel-polarized picture is taken frontally. Two images, subjects having the best effect, are supplied to the Customer.

1.7.4. Self-assessment questionnaire

Subjects are asked to express their opinion about the tested product on a self-assessment questionnaire.

1.8. Results and statistic

1.8.1. Results

- 1) Results are reported in tables in their respective units.
- 2) Mean values are calculated as:

$$m = \frac{\sum_{i=1}^n p}{n}$$

where: p is the value of the parameter under analysis; n is the number of subjects participating in the study

- 3) Percentages of subjects are calculates as follows:

$$\% \text{ of subjects} = \left(\frac{\sum_{i=1}^n \text{answers}}{n} \right) \times 100$$

where: n is the number of subjects participating in the study

- 4) Percentage variation vs. T0 is calculated as follows:

$$\%var. vs. T0 = \left(\frac{\sum_{i=1}^n \frac{p_i - p_0}{p_0}}{n} \right) \times 100$$

where: p_i is the value of the parameter under analysis after product application; p_0 is the value of the parameter under analysis before product application; n is the number of subjects participating in the study

- 5) The mean standard error of data is calculated as:

$$SEM = \frac{\sqrt{\frac{\sum_{i=1}^n (p_i^2) - \frac{(\sum_{i=1}^n p_i)^2}{n}}{n-1}}}{\sqrt{n}}$$

where: p is the value of the parameter under; n is the number of subjects participating in the study

All the calculations are done using a Microsoft® Excel 2010 (vers. 14.0.4760.1000; Microsoft, USA) worksheet running on Microsoft® Windows 8.1 Professional (Microsoft, USA).

1.8.2. Statistical analysis

Data are submitted to two-ways test t of Student (phototricogram) or to Wilcoxon test (clinical scoring). Statistical analysis is carried out using a Microsoft® Excel 2010 (vers. 14.0.4760.1000; Microsoft, USA) worksheet running on Microsoft® Windows 8.1 Professional (Microsoft, USA) and NCSS 8 (version 8.0.4 for Windows; NCSS, Kaysville, UT, USA) running on Windows Server 2008 R2 Standard SP1 64 bit edition (Microsoft, USA).

- The results of the study reported in this document are only referred to the tested samples and the specific experimental conditions.
- Any part of this report can only be reproduced with the consent of Farcoderm srl.
- A copy of this report is kept on file at Farcoderm srl.
- Both the informed consent and the information forms are kept on file at Farcoderm srl for 5 years after the date of issue of the report.

Page 8 out of 17

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it




RESULTS: PHOTOTRICHOGRAM

Table 1 The table here below reports the data obtained for each subject participating in the study. Data are reported as hair no. or %.

no.	Vol. ID	T0						T60						T90					
		Tot. No	AN	TE	%AN	%TE	AN/TE	Tot. No	AN	TE	%AN	%TE	AN/TE	Tot. No	AN	TE	%AN	%TE	AN/TE
01	V1064A	195	138	57	70,8%	29,2%	2,4	192	134	58	69,8%	30,2%	2,3	196	162	34	82,7%	17,3%	4,8
02	A0927G	223	161	62	72,2%	27,8%	2,6	220	178	42	80,9%	19,1%	4,2	226	186	40	82,3%	17,7%	4,7
03	D1405N	231	171	60	74,0%	26,0%	2,9	235	162	73	68,9%	31,1%	2,2	228	191	37	83,8%	16,2%	5,2
04	U2533V	202	142	60	70,3%	29,7%	2,4	211	171	40	81,0%	19,0%	4,3	208	168	40	80,8%	19,2%	4,2
05	B2136C	209	132	77	63,2%	36,8%	1,7	188	138	50	73,4%	26,6%	2,8	211	172	39	81,5%	18,5%	4,4
06	B2554N	165	120	45	72,7%	27,3%	2,7	168	121	47	72,0%	28,0%	2,6	172	138	34	80,2%	19,8%	4,1
07	L1763C	145	106	39	73,1%	26,9%	2,7	155	103	52	66,5%	33,5%	2,0	158	121	37	76,6%	23,4%	3,3
08	G1364A	210	145	65	69,0%	31,0%	2,2	205	173	32	84,4%	15,6%	5,4	222	178	44	80,2%	19,8%	4,0
09	S1065G	185	142	43	76,8%	23,2%	3,3	182	123	59	67,6%	32,4%	2,1	191	160	31	83,8%	16,2%	5,2
10	D1102G	205	174	31	84,9%	15,1%	5,6	208	144	64	69,2%	30,8%	2,3	211	172	39	81,5%	18,5%	4,4
11	G1922I	228	153	75	67,1%	32,9%	2,0	232	181	51	78,0%	22,0%	3,5	221	184	37	83,3%	16,7%	5,0
12	L1092P	181	132	49	72,9%	27,1%	2,7	207	156	51	75,4%	24,6%	3,1	196	161	35	82,1%	17,9%	4,6
13	C1052D	201	121	80	60,2%	39,8%	1,5	205	131	74	63,9%	36,1%	1,8	214	152	62	71,0%	29,0%	2,5
14	P1921V	213	159	54	74,6%	25,4%	2,9	201	143	58	71,1%	28,9%	2,5	193	163	30	84,5%	15,5%	5,4
15	B1438P	168	113	55	67,3%	32,7%	2,1	172	132	40	76,7%	23,3%	3,3	184	153	31	83,2%	16,8%	4,9
16	G1190P	152	110	42	72,4%	27,6%	2,6	168	114	54	67,9%	32,1%	2,1	176	131	45	74,4%	25,6%	2,9
17	C2741G	145	91	54	62,8%	37,2%	1,7	157	131	26	83,4%	16,6%	5,0	163	135	28	82,8%	17,2%	4,8
18	P0844G	185	130	55	70,3%	29,7%	2,4	170	116	54	68,2%	31,8%	2,1	187	155	32	82,9%	17,1%	4,8
19	T0394F	173	119	54	68,8%	31,2%	2,2	162	133	29	82,1%	17,9%	4,6	158	132	26	83,5%	16,5%	5,1
20	P0284N	164	119	45	72,6%	27,4%	2,6	160	124	36	77,5%	22,5%	3,4	152	122	30	80,3%	19,7%	4,1
21	G1416L	183	136	47	74,3%	25,7%	2,9	188	115	73	61,2%	38,8%	1,6	181	147	34	81,2%	18,8%	4,3
22	D0102G	164	110	54	67,1%	32,9%	2,0	168	128	40	76,2%	23,8%	3,2	171	132	39	77,2%	22,8%	3,4
23	L2083E	179	128	51	71,5%	28,5%	2,5	166	115	51	69,3%	30,7%	2,3	162	135	27	83,3%	16,7%	5,0
24	C2897F	165	107	58	64,8%	35,2%	1,8	161	128	33	79,5%	20,5%	3,9	152	132	20	86,8%	13,2%	6,6
25	R0343C	185	129	56	69,7%	30,3%	2,3	192	151	41	78,6%	21,4%	3,7	180	146	34	81,1%	18,9%	4,3
26	C0058C	202	145	57	71,8%	28,2%	2,5	214	172	42	80,4%	19,6%	4,1	224	178	46	79,5%	20,5%	3,9
27	G3213G	152	98	54	64,5%	35,5%	1,8	166	121	45	72,9%	27,1%	2,7	157	131	26	83,4%	16,6%	5,0
28	N1572V	163	117	46	71,8%	28,2%	2,5	158	135	23	85,4%	14,6%	5,9	172	143	29	83,1%	16,9%	4,9
29	Z0671M	215	144	71	67,0%	33,0%	2,0	221	142	79	64,3%	35,7%	1,8	223	172	51	77,1%	22,9%	3,4
30	D1091M	203	142	61	70,0%	30,0%	2,3	205	125	80	61,0%	39,0%	1,6	211	169	42	80,1%	19,9%	4,0
Mean		186,4	131,1	55,2	70,3%	29,7%	2,5	187,9	138,0	49,9	73,6%	26,4%	3,1	190,0	154,0	36,0	81,1%	18,9%	4,4
SEM		4,5	3,8	2,0	—	—	0,1	4,4	3,9	2,8	—	—	0,2	4,6	3,7	1,5	—	—	0,2
t-test vs. T0								0,4116	0,0494	0,1067	0,0615	0,0615	—	0,5753	0,0001	0,0000	0,0000	0,0000	0,0000

Figure 1 The figure shows the effect of the product on hair growth/loss. Data are mean $\pm$ SEM. Legend. AN Anagen hair; TE Telogen hair; *** p < 0.001.



As it is possible to notice, after a 3-months period of use, products were effective in decreasing by 10.9% the hair in the telogen phase; correspondingly the percentage of anagen hair was increase by 10.9%.

RESULTS: CLINICAL ASSESSMENT - OVERALL HAIR VOLUME AND APPERANCE

Table 2 The table here below reports the data obtained for each subject participating in the study. Data are reported as shown in the legend.

no.	Vol. ID	Hair volume				Overall hair appearance			
		T14	T30	T60	T90	T14	T30	T60	T90
01	V1064A	0	0	0	1	0	0	1	1
02	A0927G	0	1	1	1	0	1	1	1
03	D1405N	-1	0	1	2	0	0	1	1
04	U2533V	0	0	1	1	0	0	1	1
05	B2136C	0	0	1	2	0	0	1	1
06	B2554N	0	0	0	0	0	0	0	0
07	L1763C	0	0	0	0	0	1	1	1
08	G1364A	0	0	1	1	0	1	1	2
09	S1065G	0	0	0	1	0	0	0	0
10	D1102G	0	0	0	0	0	0	0	0
11	G1922I	0	0	1	1	0	0	0	0
12	L1092P	0	0	0	1	0	0	0	0
13	C1052D	0	0	1	1	0	0	1	1
14	P1921V	0	0	0	1	0	0	0	0
15	B1438P	0	0	1	1	0	0	1	1
16	G1190P	0	0	0	0	0	0	0	0
17	C2741G	0	1	2	2	0	1	1	1
18	P0844G	0	0	0	0	0	0	1	1
19	T0394F	0	0	1	1	0	1	1	2
20	P0284N	0	0	0	1	0	0	0	1
21	G1416L	0	0	0	0	0	0	0	0
22	D0102G	0	0	1	1	0	0	1	1
23	L2083E	0	0	0	0	0	0	0	0
24	C2897F	0	1	1	2	0	1	2	2
25	R0343C	0	0	0	0	0	0	0	0
26	C0058C	0	0	0	0	0	0	1	1
27	G3213G	0	0	1	2	0	0	1	1
28	N1572V	0	0	1	1	0	0	1	1
29	Z0671M	0	0	0	0	0	0	0	0
30	D1091M	0	0	0	1	0	0	0	1
% of score -3		0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
% of score -2		0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
% of score -1		3,3%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
% of score 0		96,7%	90,0%	53,3%	33,3%	100,0%	80,0%	43,3%	36,7%
% of score 1		0,0%	10,0%	43,3%	50,0%	0,0%	20,0%	53,3%	53,3%
% of score 2		0,0%	0,0%	3,3%	16,7%	0,0%	0,0%	3,3%	10,0%
% of score 3		0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
% subj. Improved		0,0%	10,0%	46,7%	66,7%	0,0%	20,0%	56,7%	63,3%

Legend

Hair volume. -3 Greatly decreased; -2 Moderately decreased; -1 Slightly decreased; 0 No change; 1 Slightly increased; 2 Moderately increased; 3 Greatly increased. | Hair appearance. -3 Greatly worsened; -2 Moderately worsened; -1 Slightly worsened; 0 No change; 1 Slightly improved; 2 Moderately improved; 3 Greatly improved.

Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it



RESULTS: SELF-ASSESSMENT AFTER 30 DAYS

Table 3a The table here below reports the self-assessment questionnaire output. Data are reported as % of subjects giving a particular response.

No.	Item	Yes	No			Positive	Negative
01	The routine is adequate to treat hair loss?	96,7%	3,3%			96,7%	3,3%
No.	Item	Completely agree	Agree	Disagree	Completely disagree	Positive	Negative
02	I noticed a decrease of hair loss	23,3%	73,3%	3,3%	0,0%	96,7%	3,3%
03	My hair are reinforced	23,3%	73,3%	0,0%	3,3%	96,7%	3,3%
04	The hair root is reinforced	23,3%	73,3%	0,0%	3,3%	96,7%	3,3%
05	I feel my hair more healthy	43,3%	50,0%	6,7%	0,0%	93,3%	6,7%
06	The product is effective	33,3%	63,3%	0,0%	3,3%	96,7%	3,3%
07	I noticed an increase of the hair strength	40,0%	60,0%	0,0%	0,0%	100,0%	0,0%
08	I feel my hair smooth and shiny	30,0%	50,0%	20,0%	0,0%	80,0%	20,0%
09	I noticed an improvement of my hair volume	30,0%	56,7%	13,3%	0,0%	86,7%	13,3%
10	Products are adequate for my type of hair	36,7%	56,7%	6,7%	0,0%	93,3%	6,7%
11	I feel an efficacy action on my scalp	26,7%	73,3%	0,0%	0,0%	100,0%	0,0%
No.	Item	Yes	No			Positive	Negative
12	Is the routine easy to follow?	100,0%	0,0%			100,0%	0,0%
No.	Item	Completely agree	Agree	Disagree	Completely disagree	Positive	Negative
13	Products are easy to use	73,3%	26,7%	0,0%	0,0%	100,0%	0,0%
No.	Item	Yes	No			Positive	Negative
14	Did you like the treatment?	93,3%	6,7%			93,3%	6,7%
No.	Item	This routine	My usual treatment	I don't know (I do not use these kind of products)		Positive	Negative
15	Did you prefer this routine or your regular routine?	56,7%	3,3%	40,0%			

RESULTS: SELF-ASSESSMENT AFTER 60 DAYS

Table 3b The table here below reports the self-assessment questionnaire output. Data are reported as % of subjects giving a particular response.

No.	Item	Yes	No			Positive	Negative
01	The routine is adequate to treat hair loss?	100,0%	0,0%			100,0%	0,0%
No.	Item	Completely agree	Agree	Disagree	Completely disagree	Positive	Negative
02	I noticed a decrease of hair loss	20,0%	76,7%	0,0%	3,3%	96,7%	3,3%
03	My hair are reinforced	33,3%	63,3%	0,0%	3,3%	96,7%	3,3%
04	The hair root is reinforced	33,3%	63,3%	0,0%	3,3%	96,7%	3,3%
05	I feel my hair more healthy	30,0%	70,0%	0,0%	0,0%	100,0%	0,0%
06	The product is effective	33,3%	66,7%	0,0%	0,0%	100,0%	0,0%
07	I noticed an increase of the hair strength	30,0%	70,0%	0,0%	0,0%	100,0%	0,0%
08	I feel my hair smooth and shiny	36,7%	50,0%	13,3%	0,0%	86,7%	13,3%
09	I noticed an improvement of my hair volume	36,7%	53,3%	10,0%	0,0%	90,0%	10,0%
10	Products are adequate for my type of hair	33,3%	66,7%	0,0%	0,0%	100,0%	0,0%
11	I feel an efficacy action on my scalp	36,7%	63,3%	0,0%	0,0%	100,0%	0,0%
No.	Item	Yes	No			Positive	Negative
12	Is the routine easy to follow?	100,0%	0,0%			100,0%	0,0%
No.	Item	Completely agree	Agree	Disagree	Completely disagree	Positive	Negative
13	Products are easy to use	70,0%	30,0%	0,0%	0,0%	100,0%	0,0%
No.	Item	Yes	No			Positive	Negative
14	Did you like the treatment?	96,7%	3,3%			96,7%	3,3%
No.	Item	This routine	My usual treatment	I don't know (I do not use these kind of products)		Positive	Negative
15	Did you prefer this routine or your regular routine?	56,7%	3,3%	40,0%			

RESULTS: SELF-ASSESSMENT AFTER 90 DAYS

Table 3c The table here below reports the self-assessment questionnaire output. Data are reported as % of subjects giving a particular response.

No.	Item	Yes	No			Positive	Negative
01	The routine is adequate to treat hair loss?	100,0%	0,0%			100,0%	0,0%
No.	Item	Completely agree	Agree	Disagree	Completely disagree	Positive	Negative
02	I noticed a decrease of hair loss	30,0%	66,7%	0,0%	3,3%	96,7%	3,3%
03	My hair are reinforced	26,7%	70,0%	0,0%	3,3%	96,7%	3,3%
04	The hair root is reinforced	26,7%	66,7%	3,3%	3,3%	93,3%	6,7%
05	I feel my hair more healthy	30,0%	70,0%	0,0%	0,0%	100,0%	0,0%
06	The product is effective	30,0%	70,0%	0,0%	0,0%	100,0%	0,0%
07	I noticed an increase of the hair strength	23,3%	76,7%	0,0%	0,0%	100,0%	0,0%
08	I feel my hair smooth and shiny	16,7%	70,0%	13,3%	0,0%	86,7%	13,3%
09	I noticed an improvement of my hair volume	26,7%	56,7%	16,7%	0,0%	83,3%	16,7%
10	Products are adequate for my type of hair	26,7%	66,7%	6,7%	0,0%	93,3%	6,7%
11	I feel an efficacy action on my scalp	30,0%	70,0%	0,0%	0,0%	100,0%	0,0%
No.	Item	Yes	No			Positive	Negative
12	Is the routine easy to follow?	93,3%	6,7%			93,3%	6,7%
No.	Item	Completely agree	Agree	Disagree	Completely disagree	Positive	Negative
13	Products are easy to use	66,7%	33,3%	0,0%	0,0%	100,0%	0,0%
No.	Item	Yes	No			Positive	Negative
14	Did you like the treatment?	86,7%	13,3%			86,7%	13,3%
No.	Item	This routine	My usual treatment	I don't know (I do not use these kind of products)		Positive	Negative
15	Did you prefer this routine or your regular routine?	53,3%	6,7%	40,0%			

Farcoderm srl


Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legatmail.it



RESULTS: SELF-ASSESSMENT SUMMARY

Figure 2 The figure summarizes the self-assessment questionnaires.



Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it



CONCLUSIONS

According to the obtained results, elsewhere reported in this document, it is possible to conclude that **REDENHAIR HAIR REGENERATOR SERUM Forte - Tónico capilar con acción anti-caída + REDENHAIR Hair Nutrition Supplement**, determines:

- ✓ an increase (+10.9% [n = +22.9 hair] vs. T0) of the % of hair in the anagen phase and a decrease (-10.9% [n = -19.3 hair] vs. T0) of the % of hair in the telogen phase, at month 3;
- ✓ an improvement of hair conditions. Hair volume was improved in the 10.0%, 46.7%, and 66.7% of the subjects, after 1, 2, and 3 months of product use, respectively. The overall hair appearance was improved in the 20.0%, 56.7% and 63.3% of the subjects, after 1, 2, and 3 months of product use, respectively.

The treatment was positively judged by the most of the subjects participating in the study. For each item in the questionnaire the percentage of subjects giving a positive answer was at least 80%.

Both REDENHAIR HAIR REGENERATOR SERUM Forte - Tónico capilar con acción anti-caída and REDENHAIR Hair Nutrition Supplement were well-tolerated by the subjects participating in the study during the test period.

Place and date of 1st emission, San Martino Siccomario, July 27th, 2016

Place and date of 1st revision, San Martino Siccomario, September 01st, 2016


Investigator
Dr. Enza Cestone
DOTT. SSA ENZA CESTONE
MEDICO CHIRURGO
SPECIALISTA IN DERMATOLOGIA E VENEREOLOGIA
V.le Cozzi, 6 - 27100 PAVIA
Part. IVA 02341110183
C.F. CST NZE 80C47 M109Z
Parere Q.d.M. PV n. 32 del 03/11/2009

Study Director & Quality control

Dr. Vincenzo Nobile

Attachment 1 - Digital pictures

The pictures here below report a subject showing the best effect.



Farcoderm srl


Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it

COMPLIFE
GROUP

Attachment 1 - Digital pictures

The pictures here below report a subject showing the best effect.



Farcoderm srl

Head Office: Piazzale Siena, 11
20146 Milan - ITALY
Production site: Via Angelini, 21
27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it

COMPLIFE
GROUP

